BioSpace News Archive

NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough cancer therapies, announces first clinical data from the ongoing Phase 1/2 study of NVG-111, a novel ROR1 targeting bispecific antibody T cell engager, in patients with relapsed and refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), in a poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Biomea Fusion, Inc. (Nasdaq: BMEA), today announced it will present new data at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrating BMF-219’s activity in ex vivo preclinical models of CLL.

Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, will present updates at the 2022 annual meeting of the American Society for Clinical Oncology in Chicago June 3-7 describing multiple applications for its next-generation liquid biopsy platform.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the quarter and year ended March 31, 2022.

New findings demonstrate the clinical efficacy of AI-powered tissue analysis as a guide in cancer treatment, according to medical AI provider Lunit.

Taiwanese biotech outfit AcadeMab has broken new ground in the development of COVID immunotherapies through the development of a potentially life-saving monoclonal antibodies for COVID-19 patients using single B cell technology, shows the best neutralization ability in both Omicron variants BA.1 and BA.2 respectively.

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that its seven clinical abstracts selected by the 2022 American Society of Clinical Oncology Annual Meeting, of which six were selected for presentations and one was selected for publication-only, have been published on the ASCO’s website.

Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it will present a Trials in Progress poster related to its ADVANCED-1 Phase 1 trial at the American Society of Clinical Oncology Annual Meeting being held in Chicago, Illinois and virtually from June 3 through June 7, 2022.

Caris Life Sciences® announced that the company and partners within its Precision Oncology Alliance™ will collectively present 45 studies across more than 20 various solid tumor types at the 2022 American Society of Clinical Oncology Annual Meeting from June 3-7, 2022.